{"organizations": [], "uuid": "48ee4e337404faaf97233e40e0540200da2e84f4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lartruvo-approved-in-canada-for-th/brief-lartruvo-approved-in-canada-for-the-treatment-of-advanced-soft-tissue-sarcoma-in-adults-idUSFWN1PJ10U", "country": "US", "domain_rank": 408, "title": "BRIEF-Lartruvo (Olaratumab) Approved In Canada For The Treatment Of Advanced Soft Tissue Sarcoma In Adults", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.972, "site_type": "news", "published": "2018-01-24T21:28:00.000+02:00", "replies_count": 0, "uuid": "48ee4e337404faaf97233e40e0540200da2e84f4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lartruvo-approved-in-canada-for-th/brief-lartruvo-approved-in-canada-for-the-treatment-of-advanced-soft-tissue-sarcoma-in-adults-idUSFWN1PJ10U", "ord_in_thread": 0, "title": "BRIEF-Lartruvo (Olaratumab) Approved In Canada For The Treatment Of Advanced Soft Tissue Sarcoma In Adults", "locations": [], "entities": {"persons": [], "locations": [{"name": "canada", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "eli lilly and co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "treatment of advanced soft tissue sarcoma", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 24 (Reuters) - Eli Lilly And Co:\n* LARTRUVO(OLARATUMAB) APPROVED IN CANADA FOR THE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA IN ADULTS\n* ELI LILLY CANADA INC - HEALTH CANADA HAS ISSUED NOTICE OF COMPLIANCE WITH CONDITIONS FOR LARTRUVO\n* ELI LILLY CANADA - CONFIRMATORY PHASE 3 TRIAL IS CURRENTLY UNDERWAY TO FURTHER VERIFY CLINICAL BENEFIT OF OLARATUMAB Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-24T21:28:00.000+02:00", "crawled": "2018-01-25T13:16:54.031+02:00", "highlightTitle": ""}